Research programme: bispecific antibodies - Janssen Biotech
Latest Information Update: 28 Jan 2026
At a glance
- Originator Janssen Biotech
- Class Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified